{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:40:38Z","timestamp":1765546838607,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Limited attention has been paid to abnormal blood and urine test results for patients with bladder cancer. The present study aimed to identify whether blood and urine parameters are associated with bladder cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a case\u2013control design and matched each patient with bladder cancer with three healthy controls of the same age and sex. Univariate conditional logistic regression was used to calculate the crude and adjusted odds ratio (OR) and its 95% CI. Multivariate conditional logistic regression was performed for confounders adjustment, and Spearman\u2019s correlation coefficient was used to assess the correlation between tumor T stages and urine parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with bladder cancer (n = 360) and controls (n = 1050) were recruited. In the univariate conditional logistic analysis, higher urine pH was associated with a decreased risk of bladder cancer (OR = 0.67, 95% CI = 0.57\u20130.78), while higher values of urine protein (OR = 4.55, 95% CI = 3.36\u20136.15), urine glucose (OR = 1.56, 95% CI = 1.18\u20132.05), and urine occult blood (OR = 4.27, 95% CI = 3.44\u20135.29) were associated with an increased risk of bladder cancer. After adjustment for body mass index, fasting blood glucose, hypertension, red blood cells, white blood cells, lymphocytes, neutrophils, and platelets, significance still remained for urine pH (OR = 0.68, 95% CI = 0.53\u20130.88), urine protein (OR = 1.97, 95% CI = 1.21\u20133.19), urine glucose (OR = 2.61, 95% CI = 1.39\u20134.89), and urine occult blood (OR = 3.54, 95% CI = 2.73\u20134.58).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study indicated that lower urine pH and higher values of urine protein, urine glucose, and urine occult blood might be risk factors for bladder cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.796975","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T04:50:23Z","timestamp":1642740623000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Can Routine Blood and Urine Parameters Reveal Clues to Detect Bladder Cancer? A Case\u2013Control Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Dan-Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Jing","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan-Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40779-021-00354-z","article-title":"Global, Regional, and National Burden of Kidney, Bladder, and Prostate Cancers and Their Attributable Risk Factors, 1990-2019","volume":"8","author":"Zi","year":"2021","journal-title":"Mil Med Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0709-9","article-title":"Impact of Gender on Bladder Cancer Incidence, Staging, and Prognosis","volume":"29","author":"Fajkovic","year":"2011","journal-title":"World J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.01.015","article-title":"The Cost to Medicare of Bladder Cancer Care","volume":"3","author":"Sloan","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1186\/s12885-019-6304-y","article-title":"Management of non-Muscle-Invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.735704","article-title":"Knowledge of and Compliance With Guidelines in the Management of Non-Muscle Invasive Bladder Cancer: A Survey of Chinese Urologists","volume":"27","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"volume-title":"EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (Tat1 and CIS)","year":"2020","author":"Babjuk","key":"B7"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X654560","article-title":"Clinical Features of Bladder Cancer in Primary Care","volume":"62","author":"Shephard","year":"2012","journal-title":"Br J Gen Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12290","article-title":"The BPSC: A Prospective Study Investigating the Clinical Effect of Interventional Therapy and the Risk Factors for Bladder Cancer and Benign Prostatic Hyperplasia in Chinese Population","volume":"11","author":"Zeng","year":"2018","journal-title":"J Evid Based Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01330","article-title":"Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients","volume":"9","author":"Zeng","year":"2018","journal-title":"Front Physiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2019.1570493","article-title":"Comparing Clinical Parameters of Abnormal and Normal Fasting Blood Glucose in Benign Prostatic Hyperplasia Patients","volume":"23","author":"Zhao","year":"2020","journal-title":"Aging Male"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20200421-00362","article-title":"[Bladder Cancer Incidence, Mortality and Temporal Trends in China]","volume":"43","author":"Li","year":"2021","journal-title":"Zhonghua zhong liu za zhi [Chinese J oncology]"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3721","article-title":"Association Between Blood Pressure and BMI With Bladder Cancer Risk and Mortality in 340,000 Men in Three Swedish Cohorts","volume":"10","author":"Teleka","year":"2021","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31597","article-title":"Risk of Bladder Cancer by Disease Severity in Relation to Metabolic Factors and Smoking: A Prospective Pooled Cohort Study of 800,000 Men and Women","volume":"143","author":"Teleka","year":"2018","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9189-9","article-title":"Glucose Metabolism Disorders in Cancer Patients in a Chinese Population","volume":"27","author":"Zhan","year":"2010","journal-title":"Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0131","article-title":"Diabetes Mellitus Increases the Risk of Bladder Cancer: An Updated Meta-Analysis of Observational Studies","volume":"15","author":"Fang","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","article-title":"Metabolic Phenotype of Bladder Cancer","volume":"45","author":"Massari","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1722","article-title":"SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database","volume":"61","author":"Garc\u00eda","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0899-9007(03)00055-8","article-title":"Integrated Analysis of Glucose, Lipid, and Urea Metabolism in Patients With Bladder Cancer. Impact of Tumor Stage","volume":"19","author":"Lattermann","year":"2003","journal-title":"Nutrition"},{"key":"B20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40779-021-00344-1","article-title":"Oral Microbiota in the Oral-Genitourinary Axis: Identifying Periodontitis as a Potential Risk of Genitourinary Cancers","volume":"8","author":"Yuan","year":"2021","journal-title":"Mil Med Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.05.014","article-title":"Prognostic Role of Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review and Meta-Analysis","volume":"36","author":"Vartolomei","year":"2018","journal-title":"Urol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.575483","article-title":"Diagnostic Value of Inflammatory Factors in Pathology of Bladder Cancer Patients","volume":"7","author":"Tang","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e23883","DOI":"10.1002\/jcla.23883","article-title":"The Predictive Value of the Ratio of the Product of Neutrophils and Hemoglobin to Lymphocytes in non-Muscular Invasive Bladder Cancer Patients With Postoperative Recurrence","volume":"35","author":"Zhao","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703033","article-title":"A Novel Nomogram Based on Machine Learning-Pathomics Signature and Neutrophil to Lymphocyte Ratio for Survival Prediction of Bladder Cancer Patients","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of Tumor-Associated Neutrophil Phenotype by TGF-Beta: \"N1\" Versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00729","article-title":"Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer","volume":"9","author":"Yin","year":"2019","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0091","DOI":"10.1097\/MD.0000000000010091","article-title":"The Clinical Significance of COL5A2 in Patients With Bladder Cancer: A Retrospective Analysis of Bladder Cancer Gene Expression Data","volume":"97","author":"Zeng","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.596484","article-title":"Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-005-0348-9","article-title":"Estimated Urine pH and Bladder Cancer Risk in a Cohort of Male Smokers (Finland)","volume":"16","author":"Wright","year":"2005","journal-title":"Cancer Causes Control"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgr048","article-title":"Urinary Ph, Cigarette Smoking and Bladder Cancer Risk","volume":"32","author":"Alguacil","year":"2011","journal-title":"Carcinogenesis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1442-2042.1995.tb00481.x","article-title":"The Etiology of Bladder Cancer\u2013are There Any New Clues or Predictors of Behavior","volume":"2","author":"Shirai","year":"1995","journal-title":"Int J Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/tx0200966","article-title":"Transformation and Activation of Benzidine by Oxidants of the Inflammatory Response","volume":"16","author":"Lakshmi","year":"2003","journal-title":"Chem Res Toxicol"},{"key":"B33","article-title":"N-Glucuronidation of Benzidine and its Metabolites. Role in Bladder Cancer","volume":"26","author":"Zenser","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"B34","article-title":"Acidic Urine pH is Associated With Elevated Levels of Free Urinary Benzidine and N-Acetylbenzidine and Urothelial Cell DNA Adducts in Exposed Workers","volume":"6","author":"Rothman","year":"1997","journal-title":"C Cancer Epidemiol Biomarkers Prev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.01.011","article-title":"The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria","volume":"126","author":"Gonzalez","year":"2019","journal-title":"Urology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1700808","DOI":"10.1002\/adhm.201700808","article-title":"An Inexpensive, Point-Of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation","volume":"6","author":"Acharya","year":"2017","journal-title":"Adv Healthc Mater"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.12.010","article-title":"A Simplified Nomogram to Assess Risk of Bladder Cancer in Patients With a New Diagnosis of Microscopic Hematuria","volume":"38","author":"Matulewicz","year":"2020","journal-title":"Urol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.796975\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T04:50:29Z","timestamp":1642740629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.796975\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":37,"alternative-id":["10.3389\/fonc.2021.796975"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.796975","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"796975"}}